Aurobindo Pharma arm ties up with European firm for biosimilars

Aurobindo Pharma subsidiary CuraTeQ Biologics has entered into a selling and organisation statement with European healthcare and pharmaceuticals institution STADA Arzneimittel AG for 2 biosimilars.

Under the agreement, STADA volition marketplace and administer 2 EMA approved biosimilars developed by CuraTeQ successful prime European Union territories, including France and Germany. New marque names volition beryllium created and registered for each biosimilar, Aurobindo Pharma said successful a filing.

The statement is expected to grow CuraTeQ’s marketplace reach, thrust gross growth, and leverage STADA’s established organisation web successful EU markets, it said.